Chairman |
Frank Wu |
Business Nature |
醫療保健 (Health Care) |
Board Members |
Chairman & Chief Executive Officer: Frank Wu Executive Director: Wu Di Non-executive Director: Jia Zhongxin, Yi Hua Independent Non-executive Director: Chui Hoi Yam, Zheng Zhelan, Li Shu Pai.
|
Principle Business |
The Group is principally engaged in the research and development of pharmaceutical products. |
Major Shareholders |
Frank Wu | 80,597,797 | H Sh | 20.31% | 26.72% | 2025/06/23 | Frank Wu | 50,259,832 | NON-H SHS | 12.66% | 52.78% | 2025/06/23 | Genecare Development Limited | 27,610,879 | H Sh | 6.96% | 9.15% | 2025/06/23 | Future Industry Investment Fund II (Limited Partnership) | 24,274,756 | H Sh | 6.12% | 8.05% | 2025/06/23 | PharmaBlock Sciences (Nanjing), Inc. | 22,107,247 | H Sh | 5.57% | 7.33% | 2025/06/23 | SDIC Venture Capital Co., Ltd | 21,680,081 | H Sh | 5.46% | 7.19% | 2025/06/23 | CPE Management International II Limited | 21,521,091 | NON-H SHS | 5.42% | 22.60% | 2025/06/23 | GP Healthcare Capital Co., Ltd. | 17,153,860 | H Sh | 4.32% | 5.69% | 2025/06/23 |
|
|
|
|
|